
|Videos|January 10, 2022
Expert Discusses How DMT Differs From Other Psychedelic Medicines
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
Advertisement
Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discussed DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.
She spoke about the benefits of DMT, what the treatment targets are, and early research of the drug.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First Oral GLP-1 for Weight Management
2
FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases
3
Achieving Optimal LDL-C Helps Prevent Neoatherosclerosis, Late Stent Failure in Patients With STEMI
4
Orforglipron Shows Strong Weight Maintenance in Phase 3 ATTAIN-MAINTAIN Trial
5







































































































































































































